Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
317.09
+2.92 (0.93%)
At close: Nov 20, 2024, 4:00 PM
320.00
+2.91 (0.92%)
Pre-market: Nov 21, 2024, 4:14 AM EST

Madrigal Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Selling, General & Admin
340.37108.1548.1337.3221.8622.65
Upgrade
Research & Development
281.71272.35245.44205.16184.8172.32
Upgrade
Operating Expenses
622.08380.5293.57242.48206.6794.97
Upgrade
Operating Income
-548.06-380.5-293.57-242.48-206.67-94.97
Upgrade
Interest Expense
-15.14-12.71-3.96---
Upgrade
Interest & Investment Income
44.5319.582.190.364.3311.02
Upgrade
Other Non Operating Income (Expenses)
---0.270.1-
Upgrade
EBT Excluding Unusual Items
-518.67-373.63-295.35-241.85-202.24-83.95
Upgrade
Pretax Income
-518.67-373.63-295.35-241.85-202.24-83.95
Upgrade
Net Income
-518.67-373.63-295.35-241.85-202.24-83.95
Upgrade
Net Income to Common
-518.67-373.63-295.35-241.85-202.24-83.95
Upgrade
Shares Outstanding (Basic)
211917171515
Upgrade
Shares Outstanding (Diluted)
211917171515
Upgrade
Shares Change (YoY)
14.83%9.05%3.64%7.05%0.34%4.04%
Upgrade
EPS (Basic)
-25.02-19.99-17.23-14.63-13.09-5.45
Upgrade
EPS (Diluted)
-25.02-19.99-17.23-14.63-13.09-5.45
Upgrade
Free Cash Flow
-433.32-325.71-225.07-184.13-157.9-41.8
Upgrade
Free Cash Flow Per Share
-20.90-17.43-13.13-11.14-10.22-2.71
Upgrade
EBITDA
-547.18-379.97-293.1-242.08-206.2-94.86
Upgrade
D&A For EBITDA
0.880.530.470.410.470.11
Upgrade
EBIT
-548.06-380.5-293.57-242.48-206.67-94.97
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.